358 related articles for article (PubMed ID: 26113483)
1. Structural and Physical Basis for Anti-IgE Therapy.
Wright JD; Chu HM; Huang CH; Ma C; Chang TW; Lim C
Sci Rep; 2015 Jun; 5():11581. PubMed ID: 26113483
[TBL] [Abstract][Full Text] [Related]
2. Allosteric mechanism of action of the therapeutic anti-IgE antibody omalizumab.
Davies AM; Allan EG; Keeble AH; Delgado J; Cossins BP; Mitropoulou AN; Pang MOY; Ceska T; Beavil AJ; Craggs G; Westwood M; Henry AJ; McDonnell JM; Sutton BJ
J Biol Chem; 2017 Jun; 292(24):9975-9987. PubMed ID: 28438838
[TBL] [Abstract][Full Text] [Related]
3. Trapping IgE in a closed conformation by mimicking CD23 binding prevents and disrupts FcεRI interaction.
Jabs F; Plum M; Laursen NS; Jensen RK; Mølgaard B; Miehe M; Mandolesi M; Rauber MM; Pfützner W; Jakob T; Möbs C; Andersen GR; Spillner E
Nat Commun; 2018 Jan; 9(1):7. PubMed ID: 29295972
[TBL] [Abstract][Full Text] [Related]
4. Structure of the omalizumab Fab.
Jensen RK; Plum M; Tjerrild L; Jakob T; Spillner E; Andersen GR
Acta Crystallogr F Struct Biol Commun; 2015 Apr; 71(Pt 4):419-26. PubMed ID: 25849503
[TBL] [Abstract][Full Text] [Related]
5. Structural basis for selective inhibition of immunoglobulin E-receptor interactions by an anti-IgE antibody.
Chen JB; Ramadani F; Pang MOY; Beavil RL; Holdom MD; Mitropoulou AN; Beavil AJ; Gould HJ; Chang TW; Sutton BJ; McDonnell JM; Davies AM
Sci Rep; 2018 Aug; 8(1):11548. PubMed ID: 30069035
[TBL] [Abstract][Full Text] [Related]
6. Engineering the Fab fragment of the anti-IgE omalizumab to prevent Fab crystallization and permit IgE-Fc complex crystallization.
Mitropoulou AN; Ceska T; Heads JT; Beavil AJ; Henry AJ; McDonnell JM; Sutton BJ; Davies AM
Acta Crystallogr F Struct Biol Commun; 2020 Mar; 76(Pt 3):116-129. PubMed ID: 32133997
[TBL] [Abstract][Full Text] [Related]
7. Ca2+-dependent structural changes in the B-cell receptor CD23 increase its affinity for human immunoglobulin E.
Yuan D; Keeble AH; Hibbert RG; Fabiane S; Gould HJ; McDonnell JM; Beavil AJ; Sutton BJ; Dhaliwal B
J Biol Chem; 2013 Jul; 288(30):21667-77. PubMed ID: 23775083
[TBL] [Abstract][Full Text] [Related]
8. A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma.
Cohen ES; Dobson CL; Käck H; Wang B; Sims DA; Lloyd CO; England E; Rees DG; Guo H; Karagiannis SN; O'Brien S; Persdotter S; Ekdahl H; Butler R; Keyes F; Oakley S; Carlsson M; Briend E; Wilkinson T; Anderson IK; Monk PD; von Wachenfeldt K; Eriksson PO; Gould HJ; Vaughan TJ; May RD
MAbs; 2014; 6(3):756-64. PubMed ID: 24583620
[TBL] [Abstract][Full Text] [Related]
9. A fluorescent biosensor reveals conformational changes in human immunoglobulin E Fc: implications for mechanisms of receptor binding, inhibition, and allergen recognition.
Hunt J; Keeble AH; Dale RE; Corbett MK; Beavil RL; Levitt J; Swann MJ; Suhling K; Ameer-Beg S; Sutton BJ; Beavil AJ
J Biol Chem; 2012 May; 287(21):17459-17470. PubMed ID: 22442150
[TBL] [Abstract][Full Text] [Related]
10. Crystal structure of IgE bound to its B-cell receptor CD23 reveals a mechanism of reciprocal allosteric inhibition with high affinity receptor FcεRI.
Dhaliwal B; Yuan D; Pang MO; Henry AJ; Cain K; Oxbrow A; Fabiane SM; Beavil AJ; McDonnell JM; Gould HJ; Sutton BJ
Proc Natl Acad Sci U S A; 2012 Jul; 109(31):12686-91. PubMed ID: 22802656
[TBL] [Abstract][Full Text] [Related]
11. The effect of omalizumab treatment on the low affinity immunoglobulin E receptor (CD23/fc epsilon RII) in patients with severe allergic asthma.
Assayag M; Moshel S; Kohan M; Berkman N
Allergy Asthma Proc; 2018 Jan; 39(1):36-42. PubMed ID: 29279058
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal study of the expression of FcεRI and IgE on basophils and dendritic cells in association with basophil function in two patients with severe allergic asthma treated with Omalizumab.
Pereira Santos MC; Campos Melo A; Caetano A; Caiado J; Mendes A; Pereira Barbosa M; Branco Ferreira M
Eur Ann Allergy Clin Immunol; 2015 Mar; 47(2):38-40. PubMed ID: 25781192
[TBL] [Abstract][Full Text] [Related]
13. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab.
Gasser P; Tarchevskaya SS; Guntern P; Brigger D; Ruppli R; Zbären N; Kleinboelting S; Heusser C; Jardetzky TS; Eggel A
Nat Commun; 2020 Jan; 11(1):165. PubMed ID: 31913280
[TBL] [Abstract][Full Text] [Related]
14. Development of small molecules to target the IgE:FcεRI protein-protein interaction in allergies.
Smith LD; Leatherbarrow RJ; Spivey AC
Future Med Chem; 2013 Aug; 5(12):1423-35. PubMed ID: 23919552
[TBL] [Abstract][Full Text] [Related]
15. Structure and dynamics of IgE-receptor interactions: FcεRI and CD23/FcεRII.
Sutton BJ; Davies AM
Immunol Rev; 2015 Nov; 268(1):222-35. PubMed ID: 26497523
[TBL] [Abstract][Full Text] [Related]
16. An anti-IgE monoclonal antibody that binds to IgE on CD23 but not on high-affinity IgE.Fc receptors.
Shiung YY; Chiang CY; Chen JB; Wu PC; Hung AF; Lu DC; Pan RL; Chang TW
Immunobiology; 2012 Jul; 217(7):676-83. PubMed ID: 22226669
[TBL] [Abstract][Full Text] [Related]
17. IgE-Related Chronic Diseases and Anti-IgE-Based Treatments.
Navinés-Ferrer A; Serrano-Candelas E; Molina-Molina GJ; Martín M
J Immunol Res; 2016; 2016():8163803. PubMed ID: 28097159
[TBL] [Abstract][Full Text] [Related]
18. Accelerated dissociation of IgE-FcεRI complexes by disruptive inhibitors actively desensitizes allergic effector cells.
Eggel A; Baravalle G; Hobi G; Kim B; Buschor P; Forrer P; Shin JS; Vogel M; Stadler BM; Dahinden CA; Jardetzky TS
J Allergy Clin Immunol; 2014 Jun; 133(6):1709-19.e8. PubMed ID: 24642143
[TBL] [Abstract][Full Text] [Related]
19. Accelerated disassembly of IgE-receptor complexes by a disruptive macromolecular inhibitor.
Kim B; Eggel A; Tarchevskaya SS; Vogel M; Prinz H; Jardetzky TS
Nature; 2012 Nov; 491(7425):613-7. PubMed ID: 23103871
[TBL] [Abstract][Full Text] [Related]
20. Omalizumab dampens type 2 inflammation in a group of long-term treated asthma patients and detaches IgE from FcεRI.
Maggi L; Rossettini B; Montaini G; Matucci A; Vultaggio A; Mazzoni A; Palterer B; Parronchi P; Maggi E; Liotta F; Annunziato F; Cosmi L
Eur J Immunol; 2018 Dec; 48(12):2005-2014. PubMed ID: 30252930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
